AnaptysBio, Inc. ANAB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$52.88M— | —— | $15.11M+139% | -$38.63M+1.8% | -$39.33M-80.5% | ||
| $130K-0.8% | $131K-6.4% | $140K-1.4% | $142K-2.7% | $146K+0.7% | ||
| $14.22M+67.2% | $8.51M-7.1% | $9.16M-0.9% | $9.24M+0.8% | $9.17M+12.0% | ||
| -$0— | —— | —— | —— | -$3.54M— | ||
| -$17.82M+20.5% | -$22.41M-20.7% | -$18.56M+16.8% | -$22.32M+7.1% | -$24.03M+40.0% | ||
| -$1.5M-54.6% | -$971K— | —— | -$414K+21.9% | -$530K-77.3% | ||
| -$8.1M— | —— | -$22.52M-52.3% | -$14.79M+35.4% | -$22.88M-134% | ||
| $8K-97.6% | $340K-69.9% | $1.13M-29.2% | $1.6M-4.2% | $1.67M-27.6% | ||
| $480K+1.1% | $475K+1.1% | $470K+2.4% | $459K-0.2% | $460K+0.9% | ||
| -$499K-1.0% | -$494K-0.8% | -$490K-2.3% | -$479K-3.7% | -$462K-1.1% | ||
| -$25.92M-126% | $98M+458% | -$27.36M+32.0% | -$40.24M-276% | -$10.7M+84.0% | ||
| $17K+1,600% | $1K-91.7% | $12K-69.2% | $39K+11.4% | $35K-86.7% | ||
| $0— | $0-100% | $19.66M-63.7% | $54.21M-55.8% | $122.55M+1.4% | ||
| $35M-52.4% | $73.5M-40.2% | $122.95M+35.6% | $90.65M-34.0% | $137.43M+49.8% | ||
| $34.98M-52.4% | $73.5M-28.8% | $103.28M+184% | $36.4M+145% | $14.85M— | ||
| $0-100% | $3.38M-65.2% | $9.72M-81.0% | $51.1M+1,055% | $4.42M+870% | ||
| $14.02M+14.8% | $12.21M+3,535% | $336K-76.4% | $1.42M+391% | $290K-47.7% | ||
| $0— | —— | —— | —— | $1.45M— | ||
| $1.21M+103% | -$43.13M-315% | -$10.39M+79.4% | -$50.5M-76.6% | -$28.59M-204% | ||
| $10.27M-92.0% | $128.36M+95.9% | $65.54M+221% | -$54.34M-122% | -$24.44M— | ||
| $20.83M-9.7% | $23.07M+9.7% | $21.03M+18.1% | $17.8M-1.6% | $18.1M-57.0% | ||
| -$8.1M+80.6% | -$41.84M-177% | $54.27M— | —— | -$22.88M-180% | ||
| -$0— | —— | —— | —— | -$3.54M— | ||
| -$499K-1.0% | -$494K-0.8% | -$490K-2.3% | -$479K-3.7% | -$462K-1.1% | ||
| -$1.5M-54.6% | -$971K— | —— | -$414K+21.9% | -$530K-77.3% | ||
| $20.86M— | —— | —— | —— | $18.06M+44.2% | ||
| $480K+1.1% | $475K+1.1% | $470K+2.4% | $459K-0.2% | $460K+0.9% | ||
| $35M-52.4% | $73.5M-40.2% | $122.95M+35.6% | $90.65M-34.0% | $137.43M+49.8% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $12.81M-75.3% | $51.96M+5,060% | $1.01M+22.4% | $823K-96.4% | $23.01M— | ||
| $23K— | $0— | —— | —— | $11K+267% | ||
| -$499K-1.0% | -$494K-0.8% | -$490K-2.3% | -$479K-3.7% | -$462K-1.1% | ||
| $8K-97.6% | $340K-69.9% | $1.13M-29.2% | $1.6M-4.2% | $1.67M-27.6% | ||
| $40K— | —— | —— | —— | $5K— | ||
| $304K— | —— | $452K— | $0— | $0— | ||
| $0— | —— | $74K— | —— | $959K— | ||
| -$25.94M-126% | $98M+458% | -$27.37M+32.1% | -$40.28M-275% | -$10.74M+84.0% | ||
| -$25.94M-126% | $98M+458% | -$27.37M+32.1% | -$40.28M-275% | -$10.74M+84.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does AnaptysBio, Inc.'s cash flow data come from?
- Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.